Compound 14J, derived from the pharmacophore assemblage of momelotinib and tandutinib, demonstrated enhanced in vitro inhibition of JAK2 and FLT3 in AML cell lines [93], enough to suggest its suitability for its use in future clinical trials. The gene discussed is JAK2; the disease is acute myeloid leukemia.